By
Irina Smith
September 6, 2024
•
10
min read
Medical devices are intended to improve our health and well-being. However, even with rigorous pre-market testing, potential safety issues may emerge only after devices are used in real-world settings. A 2018 study of FDA data revealed a startling statistic: more than 1.7 million injuries and 83,000 deaths in the United States over a 10-year period were potentially linked to medical devices. This underscores the critical need for robust post-market surveillance to ensure the safety of these devices and protect patients.
The FDA's current system relies heavily on passive surveillance, which depends on manufacturers, healthcare providers, and patients voluntarily reporting adverse events. This approach, however, has significant limitations. Underreporting, incomplete information, and time delays are common, hindering the FDA's ability to quickly identify and address potential safety risks.
Active post-market surveillance offers a vital solution. Unlike passive surveillance, it proactively seeks evidence of device performance in real-world settings. By leveraging data sources like electronic health records, billing claims, and patient registries, active surveillance can provide a more comprehensive and timely picture of device safety. This allows the FDA to detect potential safety issues that might otherwise go unnoticed, enabling quicker intervention and potentially preventing further harm to patients.
The high number of injuries and deaths potentially linked to medical devices highlights the urgency of transitioning to a more active approach. Investing in active post-market surveillance is an investment in patient safety and public health. It's about ensuring that the medical devices intended to heal us don't inadvertently cause harm.
The FDA recognizes the limitations of passive surveillance and is actively working to establish a robust active post-market surveillance system for medical devices. This commitment to patient safety is evident in the significant steps the agency has already taken:
The FDA's plan doesn't stop there. The agency has outlined an ambitious expansion strategy over the next five years.
The FDA's proactive approach to building an active surveillance system signifies a major step forward in medical device safety. By leveraging real-world evidence and embracing advanced data analytics, the FDA is paving the way for a future where medical devices are not only effective but also demonstrably safe for all patients.
Active surveillance isn't just a theoretical concept – it's a powerful tool already being used to improve patient safety. By analyzing real-world data, healthcare organizations are identifying potential device-related issues and taking action to prevent harm. Here's a real-world example of active surveillance in action:
Kaiser Permanente, a leading healthcare provider, has successfully used active surveillance to improve patient care. Leveraging data from device registries and electronic health records, they've identified medical devices with higher-than-expected revision rates. These revisions, often stemming from complications or device-associated problems, can signal potential safety concerns. By proactively identifying these trends through active surveillance, Kaiser Permanente can inform clinical decision-making, guiding physicians in selecting the safest and most effective devices for their patients.
This example illustrates how active surveillance translates into tangible benefits for patients. By shifting from a reactive to a proactive approach, we can:
Active surveillance is a critical step towards a healthcare system where medical devices consistently deliver on their promise of improving health and well-being. By embracing data-driven insights and proactive monitoring, we can create a safer and more effective healthcare landscape for all.
Explore all features of PMM for 2 weeks to see how it can simplify your post-market surveillance. If you cancel before the trial ends, your credit card will not be charged